ストックスクリーナーアプリを入手
1.27
1.55%
-0.02
アフターアワーズ：
1.27
前日終値:
$1.29
開ける：
$1.29
24時間の取引高:
76,568
Relative Volume:
0.02
時価総額：
$36.76M
収益：
$26.55M
当期純損益:
$-91.72M
株価収益率:
-0.3544
EPS:
-3.584
ネットキャッシュフロー:
$-13.25M
1週間 パフォーマンス:
-11.50%
1か月 パフォーマンス:
+82.47%
6か月 パフォーマンス:
+0.79%
1年 パフォーマンス:
-40.93%
1日の値動き範囲:
$1.27
$1.38
1週間の範囲:
$1.21
$1.45
52週間の値動き範囲:
$0.5601
$2.55
Celularity Inc Stock (CELU) Company Profile
Compare CELU vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.27 | 40.81M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Celularity (CELU) Stock News & Analysis - TechStock²
Financial Forecasts News & Analysis - TechStock²
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Singapore's MuseCell Innovations announces manufacturing collaboration with Celularity in US - BioSpectrum Asia
Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform - tradingview.com
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com India
Celularity (NASDAQ:CELU): Why Is It in Focus After It provided a fresh Nasdaq listing-compliance update? - Kalkine Media
Celularity Provides Update Regarding Nasdaq Listing Compliance - The Manila Times
Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance - Quiver Quantitative
Celularity (CELU) Latest Quarter: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Shares Move Lower 2.01% on the DayDividend Earnings Report - vinanet.vn
Celularity (CELU) Technicals: Declines 2.01% to $0.80 in the Current Update; Key Range: Support at $0.76 and Resistance at $0.84 Frame the Range on the DayWide Range Bar - dars.gov.et
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings Narrower Loss Beats Estimates by 4444 as Shares Rise 072Market Intelligence - vinanet.vn
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistanceFast Moving Stocks - dars.gov.et
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - minichart.com.sg
Celularity removes chief commercial officer Rick Gonzalez effective immediately - Investing.com
Form 8K Celularity Inc For: 7 August By Investing.com - Investing.com Nigeria
Celularity terminates Rick Gonzalez as Chief Commercial Officer - TradingView
Celularity (NASDAQ: CELU) terminates employment of chief commercial officer - Stock Titan
Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026 - marketscreener.com
Celularity Inc (CELU) Stock News Today - TradingKey
Celularity Inc (CELU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CELU|Celularity Inc|Price:0.780|Chg%:+0.030 - TradingKey
Celularity Inc (CELU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Institutional Confidence - TradingKey
Celularity Inc (CELU) Income Statement - TradingKey
TradingKey - TradingKey
Celularity Inc. (CELU) Q4 2025 Earnings: Narrower-Than-Expected Loss as Operational Discipline ImprovesSlow Growth Warning - dars.gov.et
Philip & Daniele Barach Family Trust Net Worth (2026) - GuruFocus
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
Celularity Inc (CELU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
0.79%
大文字化:
|
ボリューム (24 時間):